{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:48:10Z","timestamp":1793972890551,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K99HL157687"],"award-info":[{"award-number":["K99HL157687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["Grant 2020144"],"award-info":[{"award-number":["Grant 2020144"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41591-024-02896-w","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T07:02:02Z","timestamp":1711436522000},"page":"1199-1209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-5601","authenticated-orcid":false,"given":"Anubha","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4392-0462","authenticated-orcid":false,"given":"Priya M.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-1186","authenticated-orcid":false,"given":"Tyler","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingJing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Eileen","family":"Wafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehete","family":"Bahiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad N.","family":"de Cates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorairaj","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-2519","authenticated-orcid":false,"given":"Mark D.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2896_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019 update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982\u20133021 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2896_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","volume":"395","author":"S Yusuf","year":"2020","unstructured":"Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795\u2013808 (2020).","journal-title":"Lancet"},{"key":"2896_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"The Global Cardiovascular Risk Consortium.","year":"2023","unstructured":"The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273\u20131285 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2896_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937\u2013952 (2004).","journal-title":"Lancet"},{"key":"2896_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903\u20131913 (2002).","journal-title":"Lancet"},{"key":"2896_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 Consortium.","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 Consortium. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681 (2010).","journal-title":"Lancet"},{"key":"2896_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2003","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527\u20131535 (2003).","journal-title":"Lancet"},{"key":"2896_CR8","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/S2214-109X(21)00551-9","volume":"10","author":"ME Marcus","year":"2022","unstructured":"Marcus, M. E. et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob. Health 10, e369\u2013e379 (2022).","journal-title":"Lancet Glob. Health"},{"key":"2896_CR9","doi-asserted-by":"publisher","first-page":"e2148030","DOI":"10.1001\/jamanetworkopen.2021.48030","volume":"5","author":"AJ Nelson","year":"2022","unstructured":"Nelson, A. J. et al. Use of lipid, blood pressure, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw. Open 5, e2148030 (2022).","journal-title":"JAMA Netw. Open"},{"key":"2896_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","volume":"378","author":"S Yusuf","year":"2011","unstructured":"Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378, 1231\u20131243 (2011).","journal-title":"Lancet"},{"key":"2896_CR11","unstructured":"Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions: World Health Organization\u2013Wellcome Trust meeting report, 1\u20133 August 2001. World Health Organization https:\/\/apps.who.int\/iris\/handle\/10665\/42567 (2002)."},{"key":"2896_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","volume":"398","author":"P Joseph","year":"2021","unstructured":"Joseph, P. et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 398, 1133\u20131146 (2021).","journal-title":"Lancet"},{"key":"2896_CR13","doi-asserted-by":"publisher","unstructured":"Castellano, J. M. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2208275 (2022).","DOI":"10.1056\/nejmoa2208275"},{"key":"2896_CR14","doi-asserted-by":"publisher","unstructured":"Bahiru, E. et al. Fixed\u2010dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.cd009868.pub3 (2017).","DOI":"10.1002\/14651858.cd009868.pub3"},{"key":"2896_CR15","doi-asserted-by":"publisher","unstructured":"Cates, et al. Fixed\u2010dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst. Rev. CD009868 https:\/\/doi.org\/10.1002\/14651858.cd009868.pub2 (2014).","DOI":"10.1002\/14651858.cd009868.pub2"},{"key":"2896_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1185\/03007995.2011.555754","volume":"27","author":"J Zamorano","year":"2011","unstructured":"Zamorano, J. et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr. Med. Res. Opin. 27, 821\u2013833 (2011).","journal-title":"Curr. Med. Res. Opin."},{"key":"2896_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1751-7176.2008.00058.x","volume":"11","author":"JM Neutel","year":"2009","unstructured":"Neutel, J. M. et al. The use of a single\u2010pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo\u2010controlled, multicenter study. J. Clin. Hypertens. 11, 22\u201330 (2009).","journal-title":"J. Clin. Hypertens."},{"key":"2896_CR18","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","volume":"64","author":"JM Castellano","year":"2014","unstructured":"Castellano, J. M. et al. A polypill strategy to improve adherence results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071\u20132082 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2896_CR19","doi-asserted-by":"publisher","first-page":"g3318","DOI":"10.1136\/bmj.g3318","volume":"348","author":"V Selak","year":"2014","unstructured":"Selak, V. et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Br. Med. J. 348, g3318 (2014).","journal-title":"Br. Med. J."},{"key":"2896_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1177\/2047487314530382","volume":"22","author":"A Patel","year":"2014","unstructured":"Patel, A. et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur. J. Prev. Cardiol. 22, 920\u2013930 (2014).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2896_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1742-1241.2010.02412.x","volume":"64","author":"F Malekzadeh","year":"2010","unstructured":"Malekzadeh, F. et al. A pilot double\u2010blind randomised placebo\u2010controlled trial of the effects of fixed\u2010dose combination therapy (\u2018polypill\u2019) on cardiovascular risk factors. Int. J. Clin. Pr. 64, 1220\u20131227 (2010).","journal-title":"Int. J. Clin. Pr."},{"key":"2896_CR22","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.2147\/DDDT.S112873","volume":"10","author":"J-S Park","year":"2016","unstructured":"Park, J.-S. et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des. Dev. Ther. 10, 2599\u20132609 (2016).","journal-title":"Drug Des. Dev. Ther."},{"key":"2896_CR23","doi-asserted-by":"publisher","first-page":"e19857","DOI":"10.1371\/journal.pone.0019857","volume":"6","author":"PILL Collaborative Group.","year":"2011","unstructured":"PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (\u2018polypill\u2019) in people with raised cardiovascular risk. PLoS ONE 6, e19857 (2011).","journal-title":"PLoS ONE"},{"key":"2896_CR24","doi-asserted-by":"publisher","unstructured":"Soliman, E. Z. et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials https:\/\/doi.org\/10.1186\/1745-6215-12-3 (2011).","DOI":"10.1186\/1745-6215-12-3"},{"key":"2896_CR25","doi-asserted-by":"crossref","unstructured":"The Indian Polycap Study (TIPS). Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373, 1341\u20131351 (2009).","DOI":"10.1016\/S0140-6736(09)60611-5"},{"key":"2896_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/VHRM.S7710","volume":"6","author":"R Grimm","year":"2010","unstructured":"Grimm, R. et al. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine\/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc. Health Risk Manag. 6, 261\u2013271 (2010).","journal-title":"Vasc. Health Risk Manag."},{"key":"2896_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2013.277064","volume":"310","author":"S Thom","year":"2013","unstructured":"Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918\u2013929 (2013).","journal-title":"JAMA"},{"key":"2896_CR28","doi-asserted-by":"publisher","first-page":"e41297","DOI":"10.1371\/journal.pone.0041297","volume":"7","author":"DS Wald","year":"2012","unstructured":"Wald, D. S., Morris, J. K. & Wald, N. J. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE 7, e41297 (2012).","journal-title":"PLoS ONE"},{"key":"2896_CR29","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.clinthera.2016.09.005","volume":"38","author":"S-H Kim","year":"2016","unstructured":"Kim, S.-H. et al. Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter phase III study. Clin. Ther. 38, 2171\u20132184 (2016).","journal-title":"Clin. Ther."},{"key":"2896_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.clinthera.2018.03.010","volume":"40","author":"GC Oh","year":"2018","unstructured":"Oh, G. C. et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin. Ther. 40, 676\u2013691.e1 (2018).","journal-title":"Clin. Ther."},{"key":"2896_CR31","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.clinthera.2019.05.007","volume":"41","author":"KI Cho","year":"2019","unstructured":"Cho, K. I. et al. Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomized, double-blind, parallel phase III clinical study. Clin. Ther. 41, 1508\u20131521 (2019).","journal-title":"Clin. Ther."},{"key":"2896_CR32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","volume":"381","author":"D Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114\u20131123 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2896_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","volume":"394","author":"G Roshandel","year":"2019","unstructured":"Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672\u2013683 (2019).","journal-title":"Lancet"},{"key":"2896_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.5603\/CJ.a2020.0167","volume":"29","author":"S Chung","year":"2022","unstructured":"Chung, S. et al. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: the randomized FIXAR study. Cardiol. J. 29, 815\u2013823 (2022).","journal-title":"Cardiol. J."},{"key":"2896_CR35","doi-asserted-by":"publisher","first-page":"175394472091207","DOI":"10.1177\/1753944720912071","volume":"14","author":"J Mariani","year":"2020","unstructured":"Mariani, J. et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther. Adv. Cardiovasc. Dis. 14, 1753944720912071 (2020).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"2896_CR36","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/jch.14345","volume":"23","author":"J Choi","year":"2021","unstructured":"Choi, J. et al. Central blood pressure lowering effect of telmisartan\u2010rosuvastatin single\u2010pill combination in hypertensive patients combined with dyslipidemia: a pilot study. J. Clin. Hypertens. 23, 1664\u20131674 (2021).","journal-title":"J. Clin. Hypertens."},{"key":"2896_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.recesp.2019.11.021","volume":"74","author":"JR Gonz\u00e1lez-Juanatey","year":"2021","unstructured":"Gonz\u00e1lez-Juanatey, J. R. et al. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev. Esp. Cardiol. Engl. Ed. 74, 51\u201358 (2021).","journal-title":"Rev. Esp. Cardiol. Engl. Ed."},{"key":"2896_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa2028220","volume":"3","author":"S Yusuf","year":"2021","unstructured":"Yusuf, S. et al. Polypill with or without aspirin in persons without cardiovascular disease. N. Engl. J. Med. 3, 216\u2013228 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2896_CR39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","volume":"21","author":"S Merat","year":"2022","unstructured":"Merat, S. et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur. Heart J. 21, 2023\u20132033 (2022).","journal-title":"Eur. Heart J."},{"key":"2896_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/jch.13774","volume":"22","author":"W Kim","year":"2020","unstructured":"Kim, W. et al. A randomized, double\u2010blind clinical trial to evaluate the efficacy and safety of a fixed\u2010dose combination of amlodipine\/rosuvastatin in patients with dyslipidemia and hypertension. J. Clin. Hypertens. 22, 261\u2013269 (2020).","journal-title":"J. Clin. Hypertens."},{"key":"2896_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2022.12.003","volume":"81","author":"JZ Zhu","year":"2023","unstructured":"Zhu, J. Z. et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. J. Am. Coll. Cardiol. 81, 620\u2013622 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2896_CR42","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374, 2032\u20132043 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2896_CR43","doi-asserted-by":"publisher","first-page":"e0271908","DOI":"10.1371\/journal.pone.0271908","volume":"17","author":"R Jahangiri","year":"2022","unstructured":"Jahangiri, R. et al. Cost-effectiveness of fixed-dose combination pill (polypill) in primary and secondary prevention of cardiovascular disease: a systematic literature review. PLoS ONE 17, e0271908 (2022).","journal-title":"PLoS ONE"},{"key":"2896_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ehjqcco\/qcab101","volume":"8","author":"A Lamy","year":"2021","unstructured":"Lamy, A. et al. The cost implications of a polypill for primary prevention in the TIPS-3 trial. Eur. Hear. J. Qual. Care Clin. Outcomes 8, 899\u2013908 (2021).","journal-title":"Eur. Hear. J. Qual. Care Clin. Outcomes"},{"key":"2896_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/heapol\/czac088","volume":"1","author":"S Abimbola","year":"2023","unstructured":"Abimbola, S. & Liu, H. Adoption and scale-up of the cardiovascular polypill: a realist institutional analysis. Health Policy Plan. 1, 15\u201327 (2023).","journal-title":"Health Policy Plan."},{"key":"2896_CR46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(17)30553-6","volume":"389","author":"MD Huffman","year":"2017","unstructured":"Huffman, M. D., Xavier, D. & Perel, P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 389, 1055\u20131065 (2017).","journal-title":"Lancet"},{"key":"2896_CR47","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1001\/jama.2019.18102","volume":"322","author":"MD Huffman","year":"2019","unstructured":"Huffman, M. D., Salam, A. & Patel, A. Implementation strategies for cardiovascular polypills. JAMA 322, 2279\u20132280 (2019).","journal-title":"JAMA"},{"key":"2896_CR48","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jacc.2013.08.1665","volume":"63","author":"MD Huffman","year":"2014","unstructured":"Huffman, M. D. & Yusuf, S. Polypills essential medicines for cardiovascular disease secondary prevention? J. Am. Coll. Cardiol. 63, 1368\u20131370 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2896_CR49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5694\/mja2.51030","volume":"214","author":"R Webster","year":"2021","unstructured":"Webster, R. et al. An electronic decision support\u2010based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Med J. Aust. 214, 420\u2013427 (2021).","journal-title":"Med J. Aust."},{"key":"2896_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pcad.2022.01.005","volume":"73","author":"S Rao","year":"2022","unstructured":"Rao, S. et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials. Prog. Cardiovasc. Dis. 73, 48\u201355 (2022).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"2896_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/heartjnl-2018-313108","volume":"105","author":"V Selak","year":"2019","unstructured":"Selak, V. et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 105, 42 (2019).","journal-title":"Heart"},{"key":"2896_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.amepre.2022.03.027","volume":"63","author":"AI Abushouk","year":"2022","unstructured":"Abushouk, A. I. et al. Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis. Am. J. Prev. Med. 63, 440\u2013449 (2022).","journal-title":"Am. J. Prev. Med."},{"key":"2896_CR53","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","volume":"327","author":"United States Preventive Services Task Force","year":"2022","unstructured":"United States Preventive Services Task Forceet al. Aspirin use to prevent cardiovascular disease. JAMA 327, 1577\u20131584 (2022).","journal-title":"JAMA"},{"key":"2896_CR54","doi-asserted-by":"publisher","first-page":"924\u2013926","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924\u2013926 (2008).","journal-title":"Br. Med. J."},{"key":"2896_CR55","unstructured":"Agarwal, A. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases: a systematic review update. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=229735 (PROSPERO, 2021)."},{"key":"2896_CR56","unstructured":"Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. www.training.cochrane.org\/handbook (Cochrane, 2011)."},{"key":"2896_CR57","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br. Med. J. 366, l4898 (2019).","journal-title":"Br. Med. J."},{"key":"2896_CR58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315, 629 (1997).","journal-title":"Br. Med. J."}],"updated-by":[{"DOI":"10.1038\/s41591-024-03128-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02896-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T20:30:26Z","timestamp":1731616226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2896"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02896-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03128-x","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03128-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.H. has received travel support from the World Heart Federation. M.D.H. and A.R. have an appointment at The George Institute for Global Health, which has a patent, license and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. George Health Enterprises Pty Ltd, the social enterprise arm of the George Institute for Global Health (TGIGH), has received investment to develop fixed-dose combination products containing aspirin, statin and BP-lowering drugs. The George Institute for Global Health holds and have filed applications for combination products for the treatment of hypertension and diabetes, and A.R. is listed as one of the inventors (granted: US 10,369,15; US 10,799,487; US 10,322,117; US 11,033,544; and US 11,478,462 and pending: US 17\/932,982; US 18\/446,268; US 17\/598,122; and US 17\/317,614). A.R. is seconded part-time to George Medicines Pty Ltd, a subsidiary of George Health Enterprises. A.R. does not have a personal financial interest in these patents or products. M.D.H. and A.A. have pending patents for heart failure polypills. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}